Au

Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

Retrieved on: 
Tuesday, April 14, 2020
Cancer treatments, Clinical medicine, Cancer, Immutep, Eftilagimod alpha, LAG3, American Association for Cancer Research, Pembrolizumab

SYDNEY, Australia, April 14, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that interim Phase II TACTI-002 clinical data has been selected for a poster short talk presentation as part of the high-impact paper presentation program at the American Association for Cancer Research (AACR) Virtual Annual Meeting, scheduled for 27 and 28 April.

Key Points: 
  • SYDNEY, Australia, April 14, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that interim Phase II TACTI-002 clinical data has been selected for a poster short talk presentation as part of the high-impact paper presentation program at the American Association for Cancer Research (AACR) Virtual Annual Meeting, scheduled for 27 and 28 April.
  • This presentation was originally accepted as a late-breaking poster for the AACR Annual Meeting prior to the event being rescheduled as two virtual events due to the ongoing COVID-19 pandemic, including AACR Virtual Annual Meetings I and II.
  • The data in this presentation relates to Immuteps lead product candidate, eftilagimod alpha (efti or IMP321), a soluble LAG-3 protein based on the LAG-3 immune control mechanism, as part of a combination treatment with pembrolizumab, an anti-PD-1 therapy.

MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATO

Retrieved on: 
Thursday, April 9, 2020
Medical specialties, Medicine, Surgery, Mesoblast, Regenerative biomedicine, RTT, National Heart, Lung, and Blood Institute, Cardiothoracic surgery, Heart failure

This multi-center Phase 2/3 trial will be conducted as a public-private partnership in a collaboration with the Cardiothoracic Surgical Trials Network (CTSN), which was established by the United States National Institutes of Healths National Heart, Lung and Blood Institute (NHLBI) as a flexible platform for conducting collaborative trials.

Key Points: 
  • This multi-center Phase 2/3 trial will be conducted as a public-private partnership in a collaboration with the Cardiothoracic Surgical Trials Network (CTSN), which was established by the United States National Institutes of Healths National Heart, Lung and Blood Institute (NHLBI) as a flexible platform for conducting collaborative trials.
  • CTSN Chairman Dr A. Marc Gillinov said: We are excited to work with Mesoblast to make a real impact on the high mortality associated with COVID-19.
  • Thisrandomized controlled trialis in line with our mandate torigorously evaluate novel therapies forpublic health imperatives.
  • Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain.

Recce Signs Phase I Clinical Trial Agreement to Initiate Study of Synthetic Antibiotic RECCE® 327 in Healthy Subjects

Retrieved on: 
Wednesday, April 8, 2020
Medical specialties, Medicine, Infectious diseases, Bacterial diseases, Pathogenic bacteria, Healthcare-associated infections, Intensive care medicine, Staphylococcus aureus, Antibiotic, Sepsis, Bacteremia, Draft:Recce Pharmaceuticals Ltd

The Phase I clinical study of RECCE 327 will be conducted at a specialized clinical trial facility in Sydney, Australia, independent of the hospital system.

Key Points: 
  • The Phase I clinical study of RECCE 327 will be conducted at a specialized clinical trial facility in Sydney, Australia, independent of the hospital system.
  • This initiative seeks to ensure continuity of the independent study and not add to infectious disease pressures for beds around the country.
  • Recce Chairman Dr. John Prendergast said, The formalization of the clinical trial agreement is a major milestone towards advancing RECCE 327 through the clinic.
  • RECCE 327 is a broad-spectrum synthetic antibiotic formulated using synthetic polymer technology to treat blood infections and sepsis derived from Escherichia coli and Staphylococcus aureus bacteria.

Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer

Retrieved on: 
Wednesday, April 8, 2020
Biotechnology, Eftilagimod alpha, Immutep, RTT, Metastatic breast cancer, Breast cancer, Cancer, Health, Clinical medicine

The confirmation follows EOC Pharmas analysis of the recently reported Progression Free Survival (PFS) data, including subgroup analysis, from Immuteps phase IIb AIPAC study.

Key Points: 
  • The confirmation follows EOC Pharmas analysis of the recently reported Progression Free Survival (PFS) data, including subgroup analysis, from Immuteps phase IIb AIPAC study.
  • EOC Pharma is an oncology focused specialty pharmaceutical company headquartered in Shanghai, China, and is the exclusive licensee of efti from Immutep for the Chinese market.
  • EOC Pharma CEO, Xiaoming Zou, said: Our analysis of the overall and subgroup data suggests there is a definite opportunity to progress efti for Chinese patients with metastatic breast cancer.
  • EOC Pharma has also confirmed it will continue to advance its ongoing phase I EOC202A1101 study of eftilagimod alpha (efti or IMP321) in metastatic breast cancer in China.

MEMBRANE STUDY SUCCESS AND CORPORATE UPDATE

Retrieved on: 
Wednesday, April 8, 2020
BMN, Leverage, Bannerman, Humans

PERTH, Australia, April 08, 2020 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN, OTCQB:BNNLF, NSX:BMN) (Bannerman or the Company) is pleased to provide an update on the successful completion of the Etango project Membrane Study and corporate actions taken to maintain the Companys strong balance sheet.

Key Points: 
  • PERTH, Australia, April 08, 2020 (GLOBE NEWSWIRE) -- Bannerman Resources Limited (ASX:BMN, OTCQB:BNNLF, NSX:BMN) (Bannerman or the Company) is pleased to provide an update on the successful completion of the Etango project Membrane Study and corporate actions taken to maintain the Companys strong balance sheet.
  • We have a strong cash balance, low cash burn and an advanced, permitted project a combination that provides both extended operating runway without the need for additional capital and market-leading leverage to positive uranium dynamics.
  • This announcement was authorised to be issued by the Board of Directors.
  • For further information please contact:

Genetic Technologies Announces Closing of $1.8 Million Registered Direct Offering

Retrieved on: 
Monday, April 6, 2020
U.S. Securities and Exchange Commission, Initial public offering, Prospectus, Registration statement, Financial markets, NASDAQ, Finance, Corporate finance, 73rd United States Congress, SEC filings, Red herring prospectus

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The Securities and Exchange Commission declared effective a registration statement on Form F-3 (File No.
  • A final prospectus relating to this offering has been filed with the Securities and Exchange Commission.
  • Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company.

FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19

Retrieved on: 
Monday, April 6, 2020
Mesoblast, Regenerative biomedicine, Medical specialties, Branches of biology, Medicine, Pharmaceutical industry

Together, these outcomes provide the rationale for evaluating remestemcel-L in patients with COVID-19 ARDS.

Key Points: 
  • Together, these outcomes provide the rationale for evaluating remestemcel-L in patients with COVID-19 ARDS.
  • Mesoblast Limited (Nasdaq: MESO; ASX: MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines.
  • These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
  • Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain.

Beroni Group’s SARS-CoV-2 IgG/IgM Antibody Detection Kit Received CE Certification

Retrieved on: 
Friday, April 3, 2020
Branches of biology, Glycoproteins, Medical specialties, Medicine, Antibodies, Immunology, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Immunoglobulin G, Severe acute respiratory syndrome, Immunoglobulin M, Typhidot

Beronis SARS-CoV-2 IgG/IgM Antibody Detection Kit based on colloidal gold is a rapid single-use immunochromatographic test intended for the qualitative detection of IgG and IgM protein from the SARS-CoV-2 virus in capillary fingerstick whole blood, plasma, and serum samples.

Key Points: 
  • Beronis SARS-CoV-2 IgG/IgM Antibody Detection Kit based on colloidal gold is a rapid single-use immunochromatographic test intended for the qualitative detection of IgG and IgM protein from the SARS-CoV-2 virus in capillary fingerstick whole blood, plasma, and serum samples.
  • The point-of-care test kit is intended for professional use and delivers clinical results within 10 minutes.
  • Jacky Zhang, Chairman and CEO of Beroni Group, said, With the rapid increase in the number of coronavirus cases globally, the availability of fast and effective test kits is of utmost urgency.
  • Beroni will immediately commence discussions with potential distributors to distribute the test kit product to European Countries and other markets.

Beroni Group Included in List of Commercial Manufacturers and Laboratories Who Have Notified US FDA of Validated Serology Tests for COVID-19

Retrieved on: 
Friday, April 3, 2020
Emergency Use Authorization, Food and Drug Administration, Medical terminology, Medical tests, Point-of-care testing

The point-of-care test kit is intended for professional use and delivers clinical results within 10 minutes.

Key Points: 
  • The point-of-care test kit is intended for professional use and delivers clinical results within 10 minutes.
  • Jacky Zhang, Chairman and CEO of Beroni Group, said, With the rapid increase in the number of coronavirus cases globally, the availability of fast and effective test kits is of utmost urgency.
  • Beroni will continue to consult with the FDA about qualifying the test kit under FDAs Emergency Use Authorization.
  • Beroni will immediately commence discussions with potential distributors to distribute the test kit product to the U.S. and other markets.

STRATIS IoT Announces Platform as a Service (PaaS) Expansion with International Partner KDDI

Retrieved on: 
Thursday, April 2, 2020
KDDI, Companies, Au, Ymobile Corporation, DDI, KDD, Articles, Internet of things, Telecommunications

KDDI , a leading Japanese telecommunications company, has selected STRATIS PaaS to deliver its leading IoT initiative in Japan.

Key Points: 
  • KDDI , a leading Japanese telecommunications company, has selected STRATIS PaaS to deliver its leading IoT initiative in Japan.
  • KDDI supports au by KDDI, the mobile carrier with the highest customer satisfaction rate in Japan.
  • Through the au HOME Platform, KDDI powers smart IoT device connections.
  • "Felicite Moorman, STRATIS CEO and CoFounder stated, "We are honored to partner with KDDI, a company that exemplifies innovation and resident-centric technology.